Wang Zong-Han, Li Wei, Dong Hao, Han Fujun
Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Department of General Surgery, Second Affiliated Hospital of Jilin University, Changchun, Jilin, China.
Front Oncol. 2023 Jan 4;12:1077436. doi: 10.3389/fonc.2022.1077436. eCollection 2022.
Chronic lymphocytic leukemia (CLL) has become one of the most common hematological diseases in western countries, with an annual incidence of 42/100,000. Conventional chemotherapy and targeted therapeutic drugs showed limitations in prognosis or in efficiency in high-risk patients. Immunotherapy represented is one of the most effective therapeutic approaches with the potential of better effect and prognosis. Natural killer (NK) cells are good options for immunotherapy as they can effectively mediate anti-tumor activity of immune system by expressing activating and inhibiting receptors and recognizing specific ligands on various tumor cells. NK cells are critical in the immunotherapy of CLL by enhancing self-mediated antibody-dependent cytotoxicity (ADCC), allogeneic NK cell therapy and chimeric antigen receptor-natural killer (CAR-NK) cell therapy. In this article, we reviewed the features, working mechanisms, and receptors of NK cells, and the available evidence of the advantages and disadvantages of NK cell-based immunotherapies, and put forward future study directions in this field.
慢性淋巴细胞白血病（CLL）已成为西方国家最常见的血液系统疾病之一，年发病率为42/10万。传统化疗和靶向治疗药物在高危患者的预后或疗效方面存在局限性。免疫疗法是最有效的治疗方法之一，具有更好疗效和预后的潜力。自然杀伤（NK）细胞是免疫疗法的良好选择，因为它们可以通过表达激活和抑制受体并识别各种肿瘤细胞上的特定配体来有效介导免疫系统的抗肿瘤活性。NK细胞通过增强自身介导的抗体依赖性细胞毒性（ADCC）、同种异体NK细胞疗法和嵌合抗原受体自然杀伤（CAR-NK）细胞疗法，在CLL的免疫治疗中至关重要。在本文中，我们综述了NK细胞的特征、作用机制和受体，以及基于NK细胞的免疫疗法优缺点的现有证据，并提出了该领域未来的研究方向。
